key: cord-1026107-o1k6wk4q authors: Daoulah, Amin; Hersi, Ahmad S.; Al-Faifi, Salem M.; Alasmari, Abdulaziz; Aljohar, Alwaleed; Balghith, Mohammed; Alshehri, Mohammed; Youssef, Ali A.; ElSayed, Osama; Alama, Mohamed Nabil; Refaat, Wael A.; Alzahrani, Badr; Dahdouh, Ziad; Khan, Abdul Salim; Ghani, Mohamed A.; Soofi, Muhammad Adil; Alasnag, Mirvat; Kazim, Hameedullah M.; Elganady, Abdelmaksoud; Hassan, Taher; Ibrahim, Ahmed Mahmoud; Amellal, Zainab; Alsmadi, Faisal; Ghazi, Abdulrahman M.; Alshehri, Abdulaziz M.; Alhulayfi, Mohammed S.; Ghonim, Ahmed A.; Algazzar, Alaa S.; Garni, Turki A. AL; AlHarbi, Waleed; Jouda, Ahmed A.; Al-Shaibi, Khaled; Albasiri, Saleh; Abuelatta, Reda; Tawfik, Wael; Magdy, Mohamed; Alasmari, Sami Rashed; Selim, Ehab; Elramly, Mohamed; Abufayyah, Mohammed A.; Alshahrani, Saif S.; Alqahtani, Abdulrahman H.; Ahmed, Fatima Ali; Ahmed, Waleed A.; Lotfi, Amir title: STEMI and COVID-19 Pandemic in Saudi Arabia date: 2020-07-22 journal: Curr Probl Cardiol DOI: 10.1016/j.cpcardiol.2020.100656 sha: 1d85a78eaab1b21bfc677c8e3611c041b7ce9b15 doc_id: 1026107 cord_uid: o1k6wk4q BACKGROUND: The COVID-19 pandemic had significant impact on health care worldwide which has led to a reduction in all elective admissions and management of patients through virtual care. The purpose of this study is to assess changes in STEMI volumes, door to reperfusion, and the time from the onset of symptoms until reperfusion therapy, and in-hospital events between the pre COVID-19 (PC) and after COVID-19 (AC) period. METHODS: All acute STEMI cases were retrospectively identified from 16 centers in the Kingdom of Saudi Arabia during the COVID-19 period from January 01 to April 30, 2020. These cases were compared to a pre-COVID period from January 01 to April 30, 2018 and 2019. RESULTS: 1785 patients with a mean age 56.3 (SD ± 12.4) years, 88.3% were male. During COVID-19 Pandemic the total STEMI volumes was reduced (28%, n=500), STEMI volumes for those treated with reperfusion therapy was reduced too (27.6%, n=450). Door to balloon time < 90 minutes was achieved in (73.1%, no=307) during 2020. Timing from the onset of symptoms to the balloon of more than 12 hours was higher during 2020 comparing to pre COVID 19 years (17.2% versus <3%, respectively). There were no differences between the AC and PC period with respect to in-hospital events and the length of hospital stay. CONCLUSION: There was a reduction in the STEMI volumes during 2020. Our data reflected the standard of care for STEMI patients continued during the COVID-19 pandemic while demonstrating patients delayed presenting to the hospital. Routine inpatient and outpatient health care has been greatly disrupted by the coronavirus (COVID-19) pandemic and in order to manage the crisis both equipment and personnel have been redeployed. There has been anecdotal and publications discussing the decrease in volume of the non ST-segment elevation myocardial infarction (STEMI) and STEMI cases from around the world (1−3). One explanation for the decrease includes patients are staying home due to fear of being infected by the coronavirus and other patients presenting late in their STEMI course due to the same concerns. In patients presenting with STEMI, primary percutaneous coronary intervention (PPCI) is the accepted standard mode of treatment including during this pandemic. The Society for Cardiac Angiography and Interventions (SCAI) and American College of Cardiology (ACC) continue to recommend PPCI as the standard treatment of STEMI patients during the current pandemic (4) . The Saudi Heart Association has published guidance for acute coronary syndrome management for STEMI patients during the COVID-19 pandemic (5) . In the Kingdom of Saudi Arabia (KSA) the first reported case of COVID-19 was March 2, 2020 with a world health organization declaring COVID-19 pandemic on March 11, 2020 (6,7) . The highest number of COVID-19 cases in the Arab world has been reported in KSA with a case fatality rate of 0.7 (8) . In this study, we assessed the STEMI volumes during the COVID-19 pandemic era (January, February, March, and April 2020) comparing to pre COVID-19 era (January, February, March, and April 2018 and 2019). We also assessed door to reperfusion (balloon/needle) in order to better investigate hospital related system issues and symptom to reperfusion (balloon/needle) in order to better investigate delay in presentation. This is a retrospective, multi-center, observational study that included all consecutive hospital admissions of patients with acute STEMI. Eligible patients were above the age of 18 years, hospitalized or presenting to emergency departments with ST segment elevation of more than 1mm in more than 2 contiguous leads lasting for more than 30 minutes, or new left bundle branch block, or a clinical syndrome consistent with acute evolving transmural MI requiring immediate thrombolytic or interventional reperfusion therapy (PPCI). All acute STEMI cases were identified in 16 high-volume (>100 PPCI per year) catheterization laboratories in the Kingdom of Saudi Arabia. All of which were in tertiary hospitals during the COVID-19 era from January 01 to April 30, 2020. These cases were compared to a pre-COVID era cohort from January 01 to April 30, 2018 and 2019. Appendix 1 illustrates the total number of patients per hospital in addition to the number of Primary PCI, thrombolytic therapy, rescue PCI, and other causes of ST segment elevation who were taken to the catheterization laboratory for possible Primary PCI and had other diagnosis or those in whom the coronary anatomy was unfavorable or not feasible with percutaneous coronary intervention may undergo CABG per each hospital. No patients were excluded from this study. On March 02, 2020 the Ministry of health (MOH) announced the first case of coronavirus infection in a citizen who returned from Iran via the Kingdom of Bahrain (6) . WHO declares COVID 19 as a pandemic on March 11, 2020 (7) . Social distancing and curfew was recommended by the Saudi Center for Disease Prevention and Control (CDC) and the Saudi government respectively on March 23th (9) . The beginning of March, 2020 was identified as the beginning of the After COVID (AC) period. The first two months of 2020 (January 01 to February 29) were considered as 'COVID era' in the current study due to the variable timing of screeing measures for COVID 19 which were introduced by different centers in The Kingdom of Saudi Arabia [Jan (1 center), Feb (9 centers), March (6 centers)]. These measures followed The World Health Organization declaration that COVID was a public health emergency of international concern in Jan 30, 2020 following the outbreak that was first identified in Wuhan, China, in December 2019 (10) . The Pre COVID (PC) period for the current study was comprised of the eight months period, from Jan 1 to April 30, 2018 and 2019. A consensus statement from the cardiac services development team at the ministry of health of Saudi Arabia, recommended that all patients with acute STEMI should be considered a COVID 19 positive until proven negative, i.e. proper hand hygiene should be followed at all times, Personal Protective Equipment (PPE) for the entire staff caring for the patient should be available, a negative pressure Cath Lab should be used, all patients entering Cath Lab shouldbe wearing a face mask if tolerated (11) . To assess if there are any changes in STEMI volumes, door to balloon times, door to needle times, timing of presentation from the onset of symptoms until reperfusion therapy, in-hospital events, and length of hospital stay between the pre COVID 19 and after COVID 19 period. This Registry includes experienced cardiologists from all 16 tertiary hospitals from The Kingdom of Saudi Arabia. Multiple variables and patient factors were measured. Baseline patient characteristics were obtained from hospital records (chart review and digital library). Information collected included, age, gender, BMI, history of smoking, diabetes, hyperlipidemia, hypertension, previous history of coronary artery disease, percutaneous coronary intervention, coronary artery bypass graft, peripheral vascular disease, stroke, hospital presentation e.g. presence of cardiogenic shock (defined as a systolic blood pressure of < 90 mmHg or requirement of inotropes to maintain a SBP > 90 mmHg), sudden cardiac arrest (VA or PEA or asystole), sustained VT, symptomatic bradyarrhythmia, electrocardiographic findings, echocardiographic findings, and laboratory results includes WBCC, hemoglobin, cardiac enzymes etc. COVID 19 screening for all patients undergoing cardiac catheterization in study hospitals was based on the case definition using visual triage checklist for acute respiratory illness . A score ≥ 5 prompted testing for COVID 19 (12) . Angiographic and procedural details included identification of culprit vessels, segments and branches, other non-culprit vessels and number of stents. Timing variables were ascertained including time to presentation which is defined as the time from symptom onset until arrival at the hospital, door to balloon time, and door to needle time. In-hospital events are the events that the patient did not present with, but developed after hospitalization and included recurrent ventricular tachycardia/ventricular fibrillation (VT/VF), Symptomatic Brady-arrhythmia, congestive heart failure, cardiogenic shock, renal failure, death, stroke, recurent MI, stent thrombosis, redo PCI, implantable cardioverter defibrillator (ICD) implantation and permanent pacemaker (PPM) implantation. In addition we measure duration of in-hospital stay for each patient. All data entry from each center were checked for data queries or entry mistakes by the Principal Investigator prior to submission for final analysis. The study was approved by King Faisal Specialist Hospital and Research Center (Riyadh) Institutional Review Board and the institutional review board of each of the participating hospitals. Given the observational nature of the study and the fact that patient identities remained anonymous, the IRB did not require written informed consent. The categorical data were presented as absolute numbers and percentages. The numerical data were presented as mean ± standard deviation or as median and interquartile range, depending on the data distribution. The categorical variables were compared using chi-squared or Fisher's exact tests where indicated, and the numerical data were compared using analysis of variance (ANOVA) and Kruskal-Wallis tests for normally distributed and skewed variables, respectively. A 2-sided P value of < 0.05 was considered statistically significant. The statistical analyses were performed using SPSS, version 21 (IBM Corp., Armnok, NY). We invited a total of 16 hospitals from the 5 provinces in The Kingdom of Saudi Arabia (Makkah, Madinah, Riyadh, Asir, Eastern province). 1785 patients with acute STEMI were enrolled in the study. Cases during the COVID-19 era from January 01 to April 30, 2020 were comapared to a pre-COVID era cases from January 01 to April 30, 2018 and 2019. Of these patients, 1499 (84%) had Primary PCI, 134 (7.5%) thrombolytic therapy (alteplase 104, tenecteplase 29, streptokinase 1), 94 (5.3%) rescue PCI, and 58 (3.2%) other causes of ST segment elevation who were taken to the catheterization laboratory for possible PPCI and either had normal coronary (pericarditis 4, myocarditis 3, unknown cause 3) or coronary anatomy that was unfavorable or untreatable with percutaneous coronary intervention. This latter group were treated with surgery, CABG (18) or treated medically (diffuse multi-vessle disease 3, distal disease 6, small vessel disease 2, non-obstructive lesion 5, failed PCI 2, SCAD 2, ectatic disease 1, coronary spasm 1, havey thrombus 2, awaiting COVID 19 results 6). Table 2 . Figure (2-6) In Hospital events Table 4 , Oveall mortality rate was 4.2%. This was not significantly different between the 3 years. In-stent thrombosis were reported in 1.2% of the cohort. 1.9% of patients had redo PCI, and 3.2% undergo CABG. Bleeding rate both major and minor were reported in 1.2% and 1.6% respectively. 8.1% had cardiogenic shock. In-hospital arrhythmias both ventricular and bradyarrhythmias were reported in 4.7% and 3.9% respectively. Stroke was reported in 0.4%. Length of in-hospital stay, with a median time of 4 days (interquartile range: 3-5 days). Both in-hospital events and median length of hospital stay were not statistically different between the 3 years. We demonstrated a significant decrease in STEMI volume from 16 hospitals in 5 provinces in KSA during the COVID-19 pandemic era as compared to pre COVID-19 era. While there was no significant difference in door to reperfusion time either through PPCI or thrombolytic therapy there was a significant increase in symptom to reperfusion time. There was no difference between baseline characteristics and inpatient adverse event in STEMI patients treated during the COVID-19 pandemic timeframe versus pre COVID-19 timeframe. During the COVID-19 pandemic there have been significant concerns regarding appropriate personal protection equipment for protection of healthcare workers and concerns for patients staying away from healthcare institution for the fear of being infected with the coronavirus (13, 14) . In this retrospective analysis, as in previous studies, we demonstrated a statistically significance decrease in STEMI volume during COVID-19 era however there was no statistically significance difference in door to reperfusion indicating that hospital systems of care continued to operate efficiently. However, there symptoms to reperfusion were markedly increased during this timeframe indicating patient's hesitancy to present to the emergency department. In that context, we did not appreciate an increase in major adverse cardiovascular events, increasing biomarkers, cardiogenic shock, length of stay, and decreased ejection fraction during the inpatient stay. We cannot exclude the fact that some patients may have died from the acute cardiovascular event without seeking medical attention. The patients in our cohort as compared to the Lombardy and Kaiser Permanente (KP) cohort have significant differences (1,3). Our cohort only assessed patients with STEMI as compared to acute coronary syndrome in both studies and our cohort was younger with an average age of 55.4 ± 11.8 years versus Lombardy being 68 ± 12 years and KP being 71 ± 13.3. However, 52.1% of our cohort had diabetes mellitus with 26.8% requiring insulin, 43.8% were active smokers, and 46% had hypertension versus the KP cohort with 7.7% who were active smokers and 78% of the patient with hypertension. Even though our cohort had multiple co morbidities and increase from symptom to reperfusion time there was no significant difference in major cardiovascular inpatient outcomes Study limitations. A potential limitation is only 16 hospitals in 5 provinces were included in our study out of 35 hospitals in 13 provinces. This may have led to an overall small sample size. Nonetheless, all the Cath Lab hospitals enrolled in our registry were major tertiary centers that perform primary PCI 24 hours a day and received referrals from surrounding hospitals in their respective regions. However, this limitation was mitigated by the enrollment of the eligible hospitals in the five major provinces from all the 13 provinces of the country. Relatedly, the included hospitals were chosen using a convenience sample, and therefore a selection bias could be present. Also the possibility of missing important unmeasured variables could have been introduced, due to the observational nature of registry studies. In our study we demonstrated a significant decrease in STEMI volume during that COVID-19 era as compared to the pre-COVID 19 era with evidence of delayed presentation from time of symptom to reperfusion. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI SACIS Guidance for ACS Management for the COVID-19 Pandemic Issued 22nd WHO Declares COVID-19 a Pandemic COVID-19 in the Arab region Custodian of the Two Holy Mosques issues curfew order to limit spread of Novel Coronavirus. www.spa.gov.sa/viewfullstory.php?lang=en&newsid=2050402 World Health organization (WHO) Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCOV) AMI) PATIENTS DURING THE COVID19 PANDEMIC. A Consensus statement from the Cardiac Services Development team at the Ministry of Health of Saudi Arabia Respiratory Triage checklist for suspected COVID 19 Critical Supply Shortages -The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic Statins, n (%) 1745 (98.3%) Minor Bleeding, n (%) Major Bleeding, n (%)